Transcriptional activation of full-length and truncated lungfish MR by corticosteroids, progestins and dexamethasone.
We screened a panel of steroids (Fig. 1) at 10 nM for transcriptional activation of full-length and truncated lungfish MR containing the CDE domains (MR-CDE) using two promoters: 2X-Mouse Mammary Tumor Virus (MMTV) [54, 55] and TAT3 [53], which along with plasmids for both lungfish MRs were transfected into HEK293 cells.
As shown in Fig. 3A, there was about 2 to 3-fold activation by 10 nM aldosterone, other corticosteroids or progesterone of full-length lungfish MR using the MMTV-luc reporter and less steroid activation of lungfish MR-CDE (Fig. 3B).
Interestingly, compared to activation of full-length lungfish MR with the MMTV promoter (Fig. 3A), transcriptional activation of full-length lungfish MR with a TAT3 promoter and 10 nM aldosterone, other physiological corticosteroids or dexamethasone increased by about 1.5 to 2-fold (Fig. 3C). Unexpectedly, lungfish MR-CDE with the TAT3 promoter had an additional 2-fold increase in activation by all corticosteroids (Fig. 3D). Progesterone activated lungfish MR in accord with the prediction of Fuller et al. [37, 39, 56]. Together, these experiments show that removal of the NTD increases corticosteroid and progesterone activation of lungfish MR in the presence of the TAT3 promoter.
Our results with dexamethasone, which activates human MR [52, 57–59], were unexpected. To our surprise, compared to aldosterone, dexamethasone was about 3-fold and 6-fold more active, respectively, in activating full-length lungfish MR (Fig. 3C) and truncated lungfish MR (Fig. 3D) with the TAT3 promoter. Moreover, both cortisol and corticosterone have stronger fold-activation than does aldosterone of lungfish MR using the TAT3 promoter. Under these conditions, lungfish MR appears to have a GR-like response to steroids.
Plasmids for full-length lungfish MR or truncated lungfish MR (MR-CDE) were expressed in HEK293 cells with an MMTV-luciferase reporter or a TAT3-luciferase reporter. Transfected cells were treated with either 10 nM aldosterone, cortisol, 11-deoxycortisol, corticosterone, 11-deoxycorticosterone, progesterone, dexamethasone or vehicle alone (DMSO). Results are expressed as means ± SEM, n = 3. Y-axis indicates fold-activation compared to the activity of control vector with vehicle alone as 1. A. Full-length lungfish MR with MMTV-luciferase. B. Truncated lungfish MR (MR-CDE) with MMTV-luciferase. C. Full-length lungfish MR with TAT3-luciferase. D. Truncated lungfish MR (MR-CDE) with TAT3-luciferase.
Spironolactone and eplerenone are transcriptional activators of lungfish MR.
Because spironolactone, an antagonist of human MR, activates elephant shark MR [24], zebrafish MR [37, 40, 60] and trout MR [38], we investigated spironolactone for activation of full-length lungfish MR and truncated lungfish MR-CDE. We also studied activation by eplerenone, another antagonist of human MR [61]. As shown in Fig. 4, both spironolactone and eplerenone activated lungfish MR with a TAT3 promoter, and there was a further increase in fold-activation by both steroids of lungfish MR-CDE.
Concentration-dependent activation by corticosteroids and progestins of full-length and truncated lungfish MR.
To gain a quantitative measure of corticosteroid and progestin activation of full-length and truncated lungfish MR, we determined the concentration dependence of transcriptional activation by corticosteroids and progestins of full-length lungfish MR and lungfish MR-CDE using TAT3 (Fig. 5). This data was used to calculate a half maximal response (EC50) for steroid activation of lungfish MR with a TAT3 promoter (Table 1). For full-length lungfish MR, the four lowest EC50s were for aldosterone (0.04nM), 11-deoxycorticosterone (0.04 nM), 11-deoxycortisol (0.17nM) and progesterone (0.03nM). These low EC50s are consistent with a physiological role for one or more of these steroids as ligand for lungfish MR. In contrast, corticosterone and cortisol, two physiological corticosteroids in terrestrial vertebrates, had EC50s of 23.1nM and 66.1nM, respectively. Two synthetic glucocorticoids, dexamethasone and triamcinolone, had EC50s of 4.7nM and 1.3nM, respectively.
For truncated lungfish MR, there were similar low EC50s for aldosterone (0.24nM), 11-deoxycorticosterone (0.013nM), 11-deoxycortisol (0.27nM) and progesterone (0.04nM). EC50s for corticosterone and cortisol were 85.5nM and 86.7nM, respectively. EC50s for dexamethasone and triamcinolone were 7.7nM and 2.4nM, respectively.
Overall, these results reveal that the EC50s of aldosterone, 11-deoxycorticosterone, 11-deoxycortisol and progesterone for full-length lungfish MR and lungfish MR-CDE are similar and that one or more of these steroids could be a physiological mineralocorticoid in lungfish. Although EC50s for full-length lungfish MR of triamcinolone and dexamethasone were at least 10-fold higher than that of aldosterone, deoxycorticosterone, 11-deoxycortisol and progesterone, compared to these steroids, dexamethasone and triamcinolone have a several fold higher activation of full-length and truncated lungfish MR (Fig. 5). Consistent with data in Fig. 3, deletion of the NTD to form truncated lungfish MR-CDE increased fold-activation by aldosterone, the other corticosteroids, progesterone, dexamethasone and triamcinolone. However, deletion of the NTD did not have a large effect on their EC50s.
Table 1
EC50 values for steroid activation of full-length and truncated lungfish MR with the TAT3 promoter.
| Aldosterone | 11-deoxycorticosterone | 11-deoxycortisol | Progesterone |
| EC50 | EC50 | EC50 | EC50 |
MR-full length | 0.04 nM | 0.04 nM | 0.17 nM | 0.03 nM |
95% confidence interval | 0.02–0.07 nM | 0.02–0.09 nM | 0.1–0.3 nM | 0.02–0.06 nM |
MR-CDE | 0.24 nM | 0.13 nM | 0.27 nM | 0.044 nM |
95% confidence interval | 0.17–0.35 nM | 0.08–0.2 nM | 0.14–0.53 nM | 0.026–0.076 nM |
| Corticosterone | Cortisol | Triamcinolone | Dexamethasone |
| EC50 | EC50 | EC50 | EC50 |
MR-full length | 23.1 nM | 66.1 nM | 1.3 nM | 4.7 nM |
95% confidence interval | 11.3–47.1 nM | 44.5–98.4 nM | 0.9–1.9 nM | 3.3–6.9 nM |
MR-CDE | 85.5 nM | 86.7 nM | 2.4 nM | 7.7 nM |
95% confidence interval | 60.0-121.8 nM | 74.3-101.2 nM | 2.1–2.8 nM | 6.6–9.1 nM |
Transcriptional activation of full-length and truncated human MR and full-length and truncated elephant shark MR by corticosteroids and progestins.
To gain an evolutionary perspective on activation of lungfish MR by steroids, we screened a panel of steroids, at 10 nM, for transcriptional activation of full-length human and elephant shark MRs and truncated human and elephant shark MR-CDEs using two reporters: MMTV-luc and TAT3-luc.
Comparison of human MR and lungfish MR.
Overall, compared to lungfish MR, fold activation of human MR was significantly higher for aldosterone and other corticosteroids. For example, compared to 2-fold activation by aldosterone of full-length lungfish MR with the MMTV promoter (Fig. 3A), activation of full-length human MR by aldosterone was about 70-fold with the MMTV promoter (Fig. 6A). Although fold-activation by steroids for truncated human MR (Fig. 6B) decreased compared to full-length human MR (Fig. 6A), activation by aldosterone and other corticosteroids of truncated human MR with the MMTV promoter (Fig. 6B) was about 7-fold higher than for truncated lungfish MR (Fig. 3B).
Unlike for lungfish MR, deletion of the NTD in human MR resulted in a loss of activation by aldosterone and other corticosteroids for human MR-CDE with both promoters (Fig. 6A-D), consistent with the presence of two activation function domains in the NTD (Fig. 2) [49–52]. The relative loss of activation of human MR was greater with the MMTV promoter than with the TAT3 promoter. For example, at 10 nM aldosterone, activation of full-length human MR with the MMTV reporter was 70-fold (Fig. 6A), which decreased to 14-fold for human MR-CDE (Fig. 6B). In contrast, at 10 nM aldosterone, fold-activation of human MR-CDE with the TAT3 promoter was about 75% of activity for full-length human MR (Fig. 6C, D). However, 11-deoxycorticosterone and 11-deoxycortisol lost substantial activity for human MR-CDE with the MMTV and TAT3 promoters (Fig. 6D).
There also was higher fold-activation by aldosterone of full-length and truncated human MR with the TAT3 promoter (Fig. 6C, D) compared to full-length and truncated lungfish MR (Fig. 3C, D). Aldosterone activation of full-length human MR with the TAT3 promoter (Fig. 6C) was about 45-fold higher than that for full-length lungfish MR with the TAT3 promoter (Fig. 3C). Aldosterone activation of human MR-CDE with the TAT3 promoter (Fig. 6D) was about 15-fold higher than that for lungfish MR-CDE (Fig. 3D).
The relative activation by aldosterone and dexamethasone of human MR and lungfish MR was reversed. Aldosterone was more active than dexamethasone in stimulating transcription by full-length human MR and human MR-CDE with the TAT3 promoter (Fig. 6C, D). In contrast, for lungfish MR dexamethasone was more active than aldosterone for full-length lungfish MR and lungfish MR-CDE with the TAT3 promoter (Fig. 3C, D).
Comparison of elephant shark MR and lungfish MR.
Activation by corticosteroids and progesterone of elephant shark MR with the MMTV promoter has some similarities with their activation of lungfish MR. Like lungfish MR, corticosteroids have a similar activation of about 10-fold for full-length and truncated elephant shark MR, with little difference in potency among the corticosteroids. However, unlike lungfish MR, aldosterone is stronger than dexamethasone in activating full-length and truncated elephant shark MR with the MMTV promoter (Fig. 6E, F).
At a 10 nM steroid concentration, aldosterone and other corticosteroids activated full-length elephant shark MR with the TAT3 promoter by 9 to 12-fold (Fig. 6G), which was similar to activation with the MMTV promoter (Fig. 6E). Activation of full-length elephant shark MR by progesterone was about 5-fold with the TAT3 and MMTV promoters (Fig. 6E, G). Aldosterone was about 2-fold more active than dexamethasone.
However, deletion of the NTD from elephant shark MR resulted in a significant increase is activation by steroids in the presence of the TAT3 promoter (Fig. 6H). Thus, truncated elephant shark MR with the TAT3 promoter was activated from 300 to 350-fold by aldosterone and other corticosteroids and about 200-fold by progesterone and dexamethasone (Fig. 6H), indicating that like lungfish MR, the NTD in elephant shark inhibits activation by corticosteroids. However, unlike lungfish MR, compared to aldosterone, dexamethasone was less active for full-length and truncated elephant shark MR with the MMTV promoter and truncated elephant shark MR with the TAT3 promoter.
Does lungfish contain a separate GR gene?
We used sequences of human GR, coelacanth GR and elephant shark GR as probes in a BLAST search of GenBank and did not retrieve a lungfish GR sequence. The absence of a lungfish GR ortholog coupled with the strong response of lungfish MR to dexamethasone and triamcinolone (Fig. 5) leads us to propose that lungfish MR also functions as a GR.